uniQure (NASDAQ:QURE) Director Jack Kaye Sells 5,295 Shares of Stock

uniQure N.V. (NASDAQ:QURE) Director Jack Kaye sold 5,295 shares of the firm’s stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $42.57, for a total value of $225,408.15. Following the transaction, the director owned 25,996 shares of the company’s stock, valued at $1,106,649.72. This represents a 16.92% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jack Kaye also recently made the following trade(s):

• On Thursday, June 11th, Jack Kaye sold 1,993 shares of uniQure stock. The stock was sold at an average price of $27.06, for a total transaction of $53,930.58.
• On Wednesday, June 3rd, Jack Kaye sold 2,645 shares of uniQure stock. The stock was sold at an average price of $30.01, for a total transaction of $79,376.45.

uniQure Stock Down 4.1%

Shares of NASDAQ:QURE opened at $44.39 on Tuesday. uniQure N.V. has a 1 year low of $8.73 and a 1 year high of $71.50. The business has a 50 day simple moving average of $25.30 and a two-hundred day simple moving average of $22.30. The firm has a market capitalization of $2.80 billion, a PE ratio of -12.76 and a beta of 0.98. The company has a debt-to-equity ratio of 0.33, a current ratio of 10.40 and a quick ratio of 10.40.

uniQure (NASDAQ:QURE) last posted its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, beating the consensus estimate of ($0.88) by $0.03. The firm had revenue of $3.56 million during the quarter, compared to the consensus estimate of $5.21 million. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. On average, equities analysts predict that uniQure N.V. will post -3.64 EPS for the current year.

Institutional Investors Weigh In On uniQure

Several institutional investors and hedge funds have recently added to or reduced their stakes in QURE. Avoro Capital Advisors LLC boosted its position in uniQure by 38.4% during the fourth quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock worth $147,170,000 after acquiring an additional 1,705,556 shares during the last quarter. Aberdeen Group plc lifted its holdings in uniQure by 25.1% in the fourth quarter. Aberdeen Group plc now owns 3,678,640 shares of the biotechnology company’s stock valued at $88,030,000 after acquiring an additional 738,897 shares during the last quarter. State Street Corp grew its holdings in shares of uniQure by 123.8% during the 4th quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company’s stock worth $77,319,000 after purchasing an additional 1,787,033 shares during the period. JPMorgan Chase & Co. boosted its stake in uniQure by 155.3% during the fourth quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company’s stock worth $70,226,000 after buying an additional 1,785,275 shares during the period. Finally, Orbimed Advisors LLC boosted its position in shares of uniQure by 189.7% during the 1st quarter. Orbimed Advisors LLC now owns 2,136,149 shares of the biotechnology company’s stock worth $34,926,000 after purchasing an additional 1,398,749 shares during the period. Institutional investors and hedge funds own 78.83% of the company’s stock.

Analysts Set New Price Targets

Several research firms have commented on QURE. Chardan Capital increased their price target on shares of uniQure from $31.00 to $37.00 and gave the company a “buy” rating in a research report on Thursday, April 30th. Leerink Partners lifted their price target on uniQure from $36.00 to $70.00 and gave the stock an “outperform” rating in a research report on Thursday. Wells Fargo & Company upgraded shares of uniQure from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $15.00 to $60.00 in a research note on Monday, March 9th. Mizuho raised uniQure from a “neutral” rating to an “outperform” rating and boosted their price objective for the company from $12.00 to $35.00 in a report on Wednesday, March 11th. Finally, The Goldman Sachs Group increased their price target on shares of uniQure from $14.00 to $46.00 and gave the stock a “neutral” rating in a report on Thursday. Twelve equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $58.92.

More uniQure News

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: uniQure reported initial AMT-260 data in temporal lobe epilepsy showing meaningful seizure reductions in early patients, with no treatment-related serious adverse events, which supports the company’s gene-therapy pipeline. Article Title
• Positive Sentiment: Early trial updates also highlighted seizure reductions of 79% to 100% in three patients, reinforcing investor optimism around AMT-260’s potential. Article Title
• Neutral Sentiment: The company also announced preliminary data from the first cohort in its Phase I/IIa AMT-260 clinical trial, a routine but important catalyst for a development-stage biotech. Article Title
• Negative Sentiment: uniQure announced a $150 million underwritten public offering, with an additional $22.5 million greenshoe option, which could dilute existing shareholders even if it strengthens the balance sheet. Article Title
• Negative Sentiment: Recent insider selling by the CEO and two directors may also weigh on sentiment, even though the transactions were made under pre-arranged 10b5-1 plans. Article Title

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.